Pacific Biosciences of California, Inc. - PACB STOCK NEWS

PacBio announced the expansion of whole genome sequencing capacity at Radboud University Medical Center, increasing throughput for the SOLVE-RD program. This enhancement utilizes the PacBio Sequel IIe Systems, improving the identification of genetic variants in rare diseases. Notably, over 80% of rare disease cases are genetic, with many remaining unsolved. The system's precision is vital for detecting large variants missed by traditional methods. The program aims to sequence over 500 HiFi genomes by the end of 2022, contributing significantly to advancements in rare disease diagnostics.

PacBio announced a collaboration with Azenta Life Sciences to enhance its HiFi sequencing technology, aiming to improve genomic research capabilities globally. This partnership allows Azenta to utilize PacBio's Sequel IIe devices, expanding their genomic services to pharmaceuticals, biotechnology, and academic sectors. Azenta's strategic investment signifies a commitment to advancing research and delivering insights faster, supported by over 20 years in DNA and RNA sequencing. CEO Christian Henry emphasized the potential to redefine genomics and contribute to global health advancements.

PacBio partners with the Care4Rare Canada Consortium to explore unexplained rare disease cases using its high-resolution genome technology. The collaboration aims to improve diagnostic capabilities for rare diseases, impacting around one million Canadians, a significant portion of whom face severe health challenges. PacBio's HiFi long-read sequencing will be used to analyze samples previously sequenced by short-read technology. The goal is to enhance the understanding of rare diseases and increase diagnostic capacity, ultimately advancing patient care in Canada.

PacBio announced that its executives will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 pm ET (9:00 am PT). The event will be accessible via live webcast on the company’s investors page, with a replay available for at least 30 days after the presentation. PacBio specializes in highly accurate long-read sequencing technology, used globally in research across various scientific fields, enhancing insights into genetic variation.

PacBio (NASDAQ: PACB) has launched the HiFiViral SARS-CoV-2 solution, successfully sequencing the entire genome of the Omicron variant. This innovation provides researchers crucial genomic information, improving public health responses. The solution employs molecular inversion probes for complete genome coverage, minimizing gaps due to mutations. Validation from Inqaba Biotec showed >95% coverage for Omicron samples. The kit promises efficiency, requiring less time and fewer resources than traditional PCR methods, potentially alleviating supply chain challenges faced by labs.

PacBio (Nasdaq: PACB) has announced a research collaboration with UCLA's Institute for Precision Health and the David Geffen School of Medicine to identify the causes of rare diseases.

The partnership will utilize PacBio’s HiFi long-read sequencing technology to enhance the diagnostic yield in pediatric patients previously analyzed with short-read sequencing. UCLA's program currently sees about 50% of rare disease patients without a DNA diagnosis, and the aim is to reduce this number significantly through advanced sequencing methods.

PacBio (NASDAQ: PACB) announced the granting of stock options for 80,000 shares and restricted stock units (RSUs) for 40,000 shares to a newly hired employee under its 2020 Inducement Equity Incentive Plan. The stock options have an exercise price of $23.06, reflecting the closing price on November 29, 2021. The options will vest 25% after one year and monthly thereafter, while RSUs will vest quarterly over four years. This plan aims to attract new talent and aligns with Nasdaq rules for inducement equity grants.

PacBio (NASDAQ:PACB) appoints Jason Kang as Vice President and General Manager for the Asia-Pacific region, aiming to strengthen its commercial presence in the region. With over 25 years in the genomics industry, Kang's experience includes leadership roles at Illumina and founding Helixrus. The company's HiFi sequencing technology is seeing increased demand, and Kang's leadership is expected to facilitate further expansion. A recent keynote highlighted the opportunity for PacBio's technology in Asia-Pacific, emphasizing the growing market potential.

PacBio (NASDAQ: PACB) announced the grant of stock options and restricted stock units (RSUs) to a newly hired employee. The Compensation Committee of PacBio's Board approved non-qualified stock options for 80,000 shares and RSUs for 40,000 shares, effective November 15, 2021. The exercise price for the options is set at $26.70, matching the closing price on the effective date. The options will vest over four years, with partial vesting after one year. This grant is part of the 2020 Inducement Equity Incentive Plan, aimed at attracting new talent to the company.